Chimerix, Inc.
Chimerix, Inc. has developed a heparin-derived blood cancer drug could reduce inflammation and hypercoagulation in COVID-19 patients with acute lung injury (ALI).
Rankings by
National Ranking443rd
in United States Regional Ranking502nd
in North America and Caribbean Global Ranking1217th
worldwide